| Dr Leo Albert Millette, MD | |
|
185 Old Branchville Rd, Ridgefield, CT 06877-6013 | |
| (203) 438-3483 | |
| (860) 665-3644 |
| Full Name | Dr Leo Albert Millette |
|---|---|
| Gender | Male |
| Speciality | Preventive Medicine - Preventive Medicine/occupational Environmental Medicine |
| Location | 185 Old Branchville Rd, Ridgefield, Connecticut |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1407004955 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2083P0500X | Preventive Medicine - Preventive Medicine/occupational Environmental Medicine | 027966 (Connecticut) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Leo Albert Millette, MD 185 Old Branchville Rd, Ridgefield, CT 06877-6013 Ph: (203) 438-3483 | Dr Leo Albert Millette, MD 185 Old Branchville Rd, Ridgefield, CT 06877-6013 Ph: (203) 438-3483 |
News Archive
The immune-mediated disease SLO can lead to severe claw problems in dogs. Researchers have now identified genetic risk factors underlying this disease. The obtained results that were recently reported in the scientific journal PLoS ONE can lead to increased knowledge about similar nail diseases that affect humans.
Lymph nodes can contain large numbers of tuberculosis-causing bacteria and serve as long-term reservoirs of bacterial persistence, according to a study published November 1 in the open-access journal PLOS Pathogens by JoAnne Flynn of the University of Pittsburgh School of Medicine, and colleagues.
Anika Therapeutics, Inc. (Nasdaq: ANIK), a leader in products for tissue protection, healing and repair based on hyaluronic acid (HA) technology, today announced that it has received Health Canada approval for MONOVISC™, its single injection viscosupplement approved for the treatment of osteoarthritis of the knee. Anika expects to launch MONOVISC this month through its long-term ORTHOVISC® distribution partner in Canada, Rivex Pharma Inc., the specialty drug distribution division of Aurora, Ontario-based Helix BioPharma Corp. (TSX: HBP). MONOVISC has been broadly available in the European Union since the second quarter of 2008.
More than 5 million individuals in the United States suffer from chronic heart failure, making it one of the most common reasons for hospitalizations and readmissions. To address this costly issue, the New Jersey Hospital Association's Institute for Quality and Patient Safety this week launched a yearlong collaborative partnership to reduce hospital readmissions due to heart failure and improve the quality of healthcare in New Jersey.
Boehringer Ingelheim presented today for the first time data from a Phase II dose ranging study investigationg the combination of olodaterol, an investigational long-acting beta2-agonist (LABA), and tiotropium, a long-acting muscarinic antagonist (LAMA), in COPD patients, compared to the investigational agent olodaterol alone.
› Verified 4 days ago
Dr. Sandra Raff, MD Preventive Medicine Medicare: Not Enrolled in Medicare Practice Location: 520 Main St, Unit 15, Ridgefield, CT 06877 Phone: 203-894-5065 |